Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C13H24N4O3S.C4H4O4 |
| Molecular Weight | 432.492 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N2CCOCC2
InChI
InChIKey=WLRMANUAADYWEA-NWASOUNVSA-N
InChI=1S/C13H24N4O3S.C4H4O4/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17;5-3(6)1-2-4(7)8/h10,14,18H,4-9H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t10-;/m0./s1
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
DUOTRAV (AUTHORIZED: OCULAR HYPERTENSION)
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
||
|
NCI_THESAURUS |
C29576
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
GANFORT (AUTHORIZED: OCULAR HYPERTENSION)
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
AZARGA (AUTHORIZED: GLAUCOMA, OPEN-ANGLE)
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
GANFORT (AUTHORIZED: GLAUCOMA, OPEN-ANGLE)
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
DUOTRAV (AUTHORIZED: GLAUCOMA, OPEN-ANGLE)
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB04877MIG
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
PRIMARY | |||
|
P8Y54F701R
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
PRIMARY | |||
|
C29501
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
PRIMARY | |||
|
SUB04875MIG
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
PRIMARY | |||
|
DTXSID3047504
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
PRIMARY | |||
|
CHEMBL499
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
PRIMARY | |||
|
P8Y54F701R
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
PRIMARY | |||
|
100000090033
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
PRIMARY | |||
|
m10871
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
PRIMARY | Merck Index | ||
|
DBSALT000989
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
PRIMARY | |||
|
42933
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
PRIMARY | RxNorm | ||
|
757351
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
PRIMARY | |||
|
248-111-5
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
PRIMARY | |||
|
26921-17-5
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
PRIMARY | |||
|
5281056
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
PRIMARY | |||
|
9600
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
PRIMARY | |||
|
1667406
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
PRIMARY | |||
|
TIMOLOL MALEATE
Created by
admin on Fri Dec 15 16:03:39 UTC 2023 , Edited by admin on Fri Dec 15 16:03:39 UTC 2023
|
PRIMARY | Description: A white or almost white powder; odourless or almost odourless. Solubility: Soluble in water, methanol R, and ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Antiglaucoma drug. Storage: Timolol maleate should be kept in a well-closed container, protected from light. Requirement: Timolol maleate contains not less than 98.0% and not more than the equivalent of 101.0% of C13H24N4O3S,C4H4O4, calculated with reference to the dried substance. |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD